OraSure Technologies (OSUR) to Release Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. OraSure Technologies has set its Q1 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. The firm had revenue of $75.88 million for the quarter, compared to the consensus estimate of $74.13 million. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The company’s quarterly revenue was down 38.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.21 earnings per share. On average, analysts expect OraSure Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OraSure Technologies Price Performance

Shares of NASDAQ:OSUR opened at $5.29 on Wednesday. The company has a market cap of $404.74 million, a P/E ratio of 7.35 and a beta of 0.15. OraSure Technologies has a 1 year low of $4.38 and a 1 year high of $8.45. The stock’s fifty day moving average price is $6.27 and its 200-day moving average price is $6.81.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. StockNews.com raised OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday. Evercore ISI cut their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research note on Thursday, April 4th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.38.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.